Your browser doesn't support javascript.
loading
Hepatitis C virus: Current steps toward elimination in Germany and barriers to reaching the 2030 goal.
Sarrazin, Christoph; Boesecke, Christoph; Golsabahi-Broclawski, Solmaz; Moog, Gero; Negro, Francesco; Silaidos, Carmina; Patel, Polly; Lohmann, Kristina; Spinner, Christoph D; Walcher, Stephan; Wedemeyer, Heiner; Wörns, Marcus-Alexander.
Afiliação
  • Sarrazin C; Department of Internal Medicine and Liver Center St. Josefs-Hospital Wiesbaden and Viral Hepatitis Research Group, Goethe-University Hospital Frankfurt Frankfurt Germany.
  • Boesecke C; Department of Medicine I University Hospital Bonn Bonn Germany.
  • Golsabahi-Broclawski S; German Centre for Infection Research (DZIF) Partner-site Bonn-Cologne Bonn Germany.
  • Moog G; Medical Institute of Transcultural Medicine Bielefeld Germany.
  • Negro F; Gastroenterologische Praxis im Marienkrankenhaus Kassel Germany.
  • Silaidos C; Divisions of Gastroenterology and Hepatology and of Clinical Pathology Geneva University Hospitals Geneva Switzerland.
  • Patel P; AbbVie Deutschland GmBH Co. KG Wiesbaden Germany.
  • Lohmann K; AbbVie Inc. North Chicago Illinois.
  • Spinner CD; AbbVie Deutschland GmBH Co. KG Wiesbaden Germany.
  • Walcher S; Department of Internal Medicine II, School of Medicine, University Hospital Rechts der Isar Technical University of Munich Munich Germany.
  • Wedemeyer H; German Centre for Infection Research (DZIF), Partner Site Munich Munich Germany.
  • Wörns MA; CONCEPT, Center for Addiction-Medicine Munich Germany.
Health Sci Rep ; 4(2): e290, 2021 Jun.
Article em En | MEDLINE | ID: mdl-34136654
ABSTRACT
Hepatitis C virus (HCV) affects over 70 million people globally, with an estimated 399 000 HCV-related deaths in 2016. The World Health Organization (WHO) has set a goal to eliminate HCV by 2030. Despite the availability of direct-acting antivirals-highly effective and well-tolerated therapies for HCV-many patients infected with HCV in Germany have not initiated treatment, including a majority of those who are aware of their positive diagnosis. Barriers to screening, diagnosis, and treatment are major factors taking many countries off track for HCV elimination by 2030. Identifying country-specific barriers and challenges, particularly in at-risk populations such as people who inject drugs or men who have sex with men, has the potential to create tailored programs and strategies to increase access to screening or treatment and engage at-risk populations. This review aims to report the current steps toward HCV elimination in Germany, the country-specific barriers and challenges that will potentially prevent reaching the 2030 HCV elimination goal and describe good practice examples to overcome these barriers.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article